Tesamorelin

Overview

Tesamorelin is a stabilized synthetic analog of growth-hormone-releasing hormone (GHRH 1-44), notable among the peptides on this site as an FDA-approved prescription drug (Egrifta, approved 2010; a more concentrated reformulation, Egrifta WR, approved 2025) rather than an unapproved research chemical. Its approved indication is narrow: reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy related to antiretroviral therapy.

Proposed Mechanism of Action

As a GHRH receptor agonist, tesamorelin stimulates pulsatile release of endogenous growth hormone from the pituitary, which in turn drives IGF-1 production and lipolysis, particularly in visceral adipose tissue.

Research Context

The pivotal trial (Falutz et al., 2007, NEJM) randomized 412 HIV-infected patients to 2 mg tesamorelin or placebo, self-administered subcutaneously once daily for 26 weeks. The tesamorelin group showed a 15.2% reduction in visceral adipose tissue along with improvements in triglycerides and the total-to-HDL cholesterol ratio, without significant glucose perturbation. This trial, together with a second replication trial, formed the basis for FDA approval.

Regulatory Status and Scope

It's important not to over-generalize from this evidence: tesamorelin's approval is specific to HIV-associated lipodystrophy, under a specific dosing regimen, in a specific patient population. Use outside that approved context (e.g., for general fat loss or anti-aging purposes) has not been established by this trial and should not be assumed to carry the same safety or efficacy profile.

Limitations of the Current Evidence

• The pivotal trial population was specifically HIV patients with lipodystrophy — findings may not generalize to other populations or indications.
• As with any GH-axis agent, long-term safety data outside the studied population and duration is limited.